Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia
Purwati et al., PLOS One, doi:10.1371/journal.pone.0252302 (In Vitro)
Purwati et al., An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine.., PLOS One, doi:10.1371/journal.pone.0252302 (In Vitro)
Jun 2021   Source   PDF  
  All Studies   Meta
In Vitro study of combinations of drugs showing antiviral efficacy of HCQ alone and in combination with AZ, favipiravir, and doxycycline. No high levels of cytotoxicity were observed, and authors conclude that using a combination of drugs can reduce the degree of cytotoxicity, increase antiviral activity, reduce the effect on pro-inflammatory markers, and increase anti-inflammatory response.
14 In Vitro studies support the efficacy of HCQ [Andreani, Clementi, Dang, Delandre, Faísca, Hoffmann, Liu, Ou, Purwati, Sheaff, Wang, Wang (B), Yao, Yuan].
Purwati et al., 18 Jun 2021, peer-reviewed, 16 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: PLOS ONE RESEARCH ARTICLE An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 OPEN ACCESS Citation: Purwati , Miatmoko A, Nasronudin , Hendrianto E, Karsari D, Dinaryanti A, et al. (2021) An in vitro study of dual drug combinations of antiviral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia. PLoS ONE 16(6): e0252302. journal.pone.0252302 Editor: Mrinmoy Sanyal, Stanford University School of Medicine, UNITED STATES Received: October 9, 2020 Accepted: May 13, 2021 Published: June 18, 2021 Copyright: © 2021 Purwati et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files. Funding: This study was funded by State Intelligence Agency (BIN) of Republic of Indonesia. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Purwati ID1,2,3*, Andang Miatmoko1,4, Nasronudin5, Eryk Hendrianto1, Deya Karsari1, Aristika Dinaryanti1, Nora Ertanti1, Igo Syaiful Ihsan1, Disca Sandyakala Purnama1, Tri Pudy Asmarawati5, Erika Marfiani5, Yulistiani4,5, Alfian Nur Rosyid5, Prastuti Asta Wulaningrum5, Herley Windo Setiawan5, Imam Siswanto6, Ni Nyoman Tri Puspaningsih7 1 Stem Cell Research and Development Center, Institute of Tropical Disease, Universitas Airlangga, Mulyorejo, Surabaya, Indonesia, 2 Faculty of Vocations, Universitas Airlangga, Gubeng, Surabaya, Indonesia, 3 Department of Biotechnology, Asia University, Wufeng, Taichung, Taiwan, 4 Faculty of Pharmacy, Universitas Airlangga, Mulyorejo, Surabaya, Indonesia, 5 Rumah Sakit Umum dan Rumah Sakit Khusus Infeksi, Universitas Airlangga, Mulyorejo, Surabaya, Indonesia, 6 Bioinformatic Laboratory, UCoE Research Center for Bio-Molecule Engineering Universitas Airlangga, Surabaya, Indonesia, 7 Department of Chemistry, Faculty of Science and Technology, Universitas Airlangga, Surabaya, Indonesia * Abstract A potent therapy for the infectious coronavirus disease COVID-19 is urgently required with, at the time of writing, research in this area still ongoing. This study aims to evaluate the in vitro anti-viral activities of combinations of certain commercially available drugs that have recently formed part of COVID-19 therapy. Dual combinatory drugs, namely; LopinavirRitonavir (LOPIRITO)-Clarithromycin (CLA), LOPIRITO-Azithromycin (AZI), LOPIRITODoxycycline (DOXY), Hydroxychloroquine (HCQ)-AZI, HCQ-DOXY, Favipiravir (FAVI)-AZI, HCQ-FAVI, and HCQ-LOPIRITO, were prepared. These drugs were mixed at specific ratios and evaluated for their safe use based on the cytotoxicity concentration (CC50) values of human umbilical cord mesenchymal stem cells. The anti-viral efficacy of these combinations in relation to Vero cells infected with SARS-CoV-2 virus isolated from a patient in Universitas Airlangga hospital, Surabaya, Indonesia and evaluated for IC50 24, 48, and 72 hours after viral inoculation was subsequently determined...
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop